Table 2 Patient characteristics
| Â | Retrospective cohort | Prospective cohort | Combination cohort | |||
|---|---|---|---|---|---|---|
Non-PCa | PCa | Non-PCa | PCa | Non-PCa | PCa | |
Patients (%) | 94 (15.3%) | 520 (84.7%) | 189 (47.7%) | 207 (52.3%) | 283 (28.0%) | 727 (72.0%) |
Mean age (year) | 64 (41–84) | 64 (45–78) | 69 (45–86) | 69 (39–88) | 68 (41–86) | 65 (39–88) |
Patients with other cancers (%) | 1 (1.1%) | 4 (0.8%) | 2 (1.1%) | 1 (0.5%) | 3 (1.1%) | 5 (0.7%) |
Gleason score (%) | Â | Â | Â | Â | Â | Â |
Group 1: ≤ 6 (≤ 3 + 3) | NA | 124 (23.8%) | NA | 39 (18.8%) | NA | 163 (22.4%) |
Group 2: 7 (3 + 4) | NA | 218 (41.9%) | NA | 54 (26.1%) | NA | 272 (37.4%) |
Group 3: 7 (4 + 3) | NA | 136 (26.2%) | NA | 55 (26.6%) | NA | 191 (26.3%) |
Group 4: 8 (4 + 4, 3 + 5, 5 + 3) | NA | 17 (3.3%) | NA | 30 (14.5%) | NA | 47 (6.5%) |
Group 5: 9 or 10 (4 + 5, 5 + 4, or 5 + 5) | NA | 25 (4.8%) | NA | 29 (14.0%) | NA | 54 (7.4%) |
Mean PSA (ng/mL) | 10.1 | 6.1 | 10.6 | 67.9 | 10.51 | 65.0 |